Welcome to our dedicated page for Phibro Animal news (Ticker: PAHC), a resource for investors and traders seeking the latest updates and insights on Phibro Animal stock.
Phibro Animal Health Corporation reports developments in animal health, mineral nutrition and performance products for food-animal markets. The company develops, manufactures and markets antibacterials, anticoccidials, nutritional specialty products, vaccines and mineral nutrition products for poultry, swine, beef and dairy cattle, and aquaculture in the United States and international markets.
Recurring PAHC news includes quarterly results and guidance, cash dividend declarations on Class A and Class B common stock, investor conference participation and regulatory updates affecting antimicrobial products such as virginiamycin and bacitracin. Company updates also address product portfolio activity, acquisition-related effects, input and distribution costs, foreign-currency impacts and tools such as PhibroVet for veterinary prescription management.
Phibro Animal Health (Nasdaq: PAHC) will release second quarter results on Wednesday, February 4, 2026 after market close and will host a conference call and webcast on Thursday, February 5, 2026 at 9:00 AM ET.
Investors can join live via the investor site, dial +1 (888) 330-2022 (U.S./Canada) or +1 (365) 977-0051 (international) using conference ID 3927884. A replay will be available about two hours after the live event on the investor website.
Phibro Animal Health (Nasdaq: PAHC) announced a planned leadership transition effective July 1, 2026. Jack Bendheim will move from CEO and President to Executive Chairman while remaining Board Chairman. Daniel (Dani) Bendheim will become Chief Executive Officer and President. Jack has led the company since 1969, served as President since 1988 and was CEO since March 2014. Dani joined in 1997 and has held roles including VP of Business Development, President of Performance Products, Executive VP Corporate Strategy and most recently Chief Transformation Officer overseeing the Phibro Forward initiative. The Board gave unanimous support and the full executive team will remain in place.
Phibro Animal Health (Nasdaq: PAHC) reported a strong start to fiscal 2026 for the quarter ended September 30, 2025, with net sales of $363.9M (up 40%) and net income $26.5M. Animal Health sales rose 55% to $283.5M driven by MFAs, nutritional specialties and vaccines. Adjusted EBITDA for the quarter was $61.9M and management raised FY2026 adjusted EBITDA guidance to $230M–$240M while maintaining net sales guidance of $1.43B–$1.48B. Balance sheet highlights include $749.1M total debt, 3.3x gross leverage and $85.3M cash and short-term investments.
Phibro Animal Health Corporation (Nasdaq: PAHC) declared a quarterly cash dividend of $0.12 per share on both Class A and Class B common stock. The dividend is payable on December 17, 2025 to stockholders of record at the close of business on November 26, 2025. The declaration was made by the Board of Directors in Teaneck, NJ.
Phibro Animal Health (NASDAQ:PAHC) announced the national launch of Restoris piezoelectric dental gel for dogs with periodontal disease on October 30, 2025. Restoris, developed with a U.S. dental school and licensed to Phibro, is applied into periodontal pockets, cured with supplied UV light, and uses piezoelectric particles to generate microcurrents that stimulate osteoblasts.
Clinical and laboratory studies showed significant reductions in periodontal pocket depth and generation of alveolar bone around the treated tooth within 30 days. Restoris is available for pre-order from Patterson Veterinary Supply and will ship within the next 30 days.
Phibro Animal Health (Nasdaq: PAHC) expects to announce its first quarter results on Wednesday, November 5, 2025 after market close. Management will host a conference call and webcast on Thursday, November 6, 2025 at 9:00 AM Eastern Time.
Investors can access the live presentation and slides at https://investors.pahc.com or dial +1 (888) 330-2022 (U.S./Canada) or +1 (365) 977-0051 (international) and provide conference ID 3927884. A replay of the webcast will be available approximately two hours after the live event at https://investors.pahc.com.
Phibro Animal Health (Nasdaq: PAHC) announced on October 9, 2025 an exclusive licensing agreement with Lighthouse Pharmaceuticals to develop, manufacture, and commercialize a proprietary compound for canine periodontal health. Phibro will lead global regulatory, commercial, and distribution efforts while Lighthouse advances its gingipain inhibitor platform. The compound has shown preclinical efficacy and safety. Financial terms were not disclosed. The collaboration targets improved veterinary periodontal care and potential long‑term benefits for dogs and companion animal portfolios.
Phibro Animal Health Corporation (Nasdaq: PAHC) announced its participation in the upcoming Morgan Stanley Annual Global Healthcare Conference. CFO Glenn David will present to financial analysts and investors on September 9, 2025, at 12:20 PM ET at the Sheraton New York Times Square Hotel.
The presentation will be accessible via live audio stream on the company's investor relations website, with a replay available for later viewing.
Phibro Animal Health (NASDAQ:PAHC) reported strong financial results for Q4 and fiscal year 2025, with significant growth across key metrics. The company achieved Q4 net sales of $378.7M (up 39%) and net income of $17.2M (up $16.5M), with diluted EPS of $0.42.
For FY2025, PAHC reported net sales of $1.29B (up 27%), net income of $48.3M, and adjusted EBITDA of $183.7M (up 65%). The growth was primarily driven by the successful integration of the Zoetis MFA portfolio and strong performance across Animal Health segments.
Looking ahead, PAHC provided FY2026 guidance with projected net sales of $1.43-1.48B and adjusted EBITDA of $225-235M, reflecting continued confidence in their growth trajectory.
Phibro Animal Health Corporation (Nasdaq: PAHC) has scheduled its fourth quarter and fiscal year 2025 financial results announcement for Wednesday, August 27, 2025, after market close. The company will host a conference call and webcast to discuss the results on Thursday, August 28, 2025, at 9:00 AM Eastern Time.
Investors can access the presentation through the company's investor relations website at https://investors.pahc.com or join via phone using the provided dial-in numbers. A replay of the webcast will be made available approximately two hours after the event concludes.